Furthermore, common single-nucleotide polymorphisms (SNPs) such as rs2853669 found at the TERT promoter have been shown to modify the survival and prognosis of certain cancers carrying TERT promoter mutations [59], such as clear cell renal cell carcinoma, melanoma and glioblastoma, where patients exhibit improved survival in the presence of this polymorphism [60,61,62], plausibly through disruption of an adjacent ETS2 binding site [42,63]. This evidence concerns the gene TERT and melanoma.